Leading Asia-Pacific biotech specialist CRO Novotech and Medidata renew 
partnership, further expanding services to Novotech clients in APAC and the US



Medidata, a Dassault Systèmes company, today announced its renewed, expanded 
partnership with Novotech, a leading contract research organisation (CRO), to 
continue scaling clinical studies in various therapeutic areas from 2022.

Leveraging Rave EDC, Rave RTSM, eCOA and eConsent technology from Medidata, 
Novotech is equipped with flexible, configurable tools that can address 
clinical research needs at scale and facilitate accelerated drug and device 
development in Asia Pacific and the U.S.

Since its partnership in 2018, Novotech has doubled its growth and has also 
acquired CRO companies in APAC and the U.S. as well as invested in advanced DCT 
and data companies to deliver a seamless CRO platform amidst the increasing 
demand for clinical trials services in the region. The partnership extends 
access to a suite of end-to-end solutions from Medidata Clinical Cloud 
(https://www.medidata.com/en/clinical-trial-products/unified-platform), the 
industry's only unified platform dedicated to clinical research. It also 
underscores Medidata and Novotech's commitment to work collaboratively towards 
accelerating clinical trials and research efficiently, while improving clinical 
trial timelines and patient experiences.

The Medidata Clinical Cloud is the only unified technology platform dedicated 
to clinical research, with solutions that leverage centralized data to address 
the holistic research process from start to finish. With the physical 
limitations and fragmentation of healthcare ecosystems caused by the COVID-19 
pandemic, the need for digital integration for accelerated clinical development 
is crucial, and a unified platform allows for streamlined management of 
studies, sites, users, and access from a single location.

Edwin Ng, Senior Vice President, Asia Pacific, Medidata, commented, "The 
pandemic has underscored the importance of redesigning how trials are run, with 
more stakeholders realising the vital role that technology plays in clinical 
development. Medidata is pleased to continue our strong partnership with 
Novotech and is dedicated to providing support in their acceleration of 
clinical studies. Working with leading technologies, we can deliver better 
patient experiences and accelerate drug development in the new normal in 
clinical research." 

Andries Claassen, Senior Director Biometrics, Novotech, added, "We are excited 
to continue our partnership with Medidata, with their sustained support in 
driving clinical research and business growth with customers. Novotech has 
always invested heavily in the latest technology to provide our clients with 
better data visibility for improved decision-making. Together, we will help 
sponsors deliver more efficient, effective, and scalable trials."

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 
3DEXPERIENCE platform is positioned to lead the digital transformation of life 
sciences in the age of personalized medicine with the first end-to-end 
scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope 
for millions of patients. Medidata helps generate the evidence and insights to 
help pharmaceutical, biotech, medical device and diagnostics companies, and 
academic researchers accelerate value, minimize risk, and optimize outcomes. 
More than one million registered users across 2,000+ customers and partners 
access the world's most trusted platform for clinical development, commercial, 
and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: 
FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around 
the world to meet the needs of its customers. Discover more at www.medidata.com 
and follow us @Medidata (http://twitter.com/Medidata).

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. 
We provide business and people with collaborative 3D virtual environments to 
imagine sustainable innovations. By creating virtual twin experiences of the 
real world with our 3DEXPERIENCE platform and applications, our customers push 
the boundaries of innovation, learning and production to achieve a more 
sustainable world for patients, citizens, and consumers.  Dassault Systèmes 
brings value to more than 300,000 customers of all sizes, in all industries, in 
more than 140 countries. For more information, visit www.3ds.com/.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, 
SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, 
DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault 
Systèmes, a French "société européenne" (Versailles Commercial Register # B 322 
306 440), or its subsidiaries in the United States and/or other countries.

About Novotech 

Novotech is the leading Asia Pacific biotech specialist CRO with labs, phase I 
facilities, and drug development consulting services.  Novotech has accumulated 
experience in over 3,700 clinical projects, including Phase I to Phase IV 
clinical trials and bioequivalence studies. Novotech is positioned to serve 
biopharmaceutical clients conducting clinical trials in Asia and globally and 
serves biotechs globally leveraging deep relationships built with hundreds of 
Asia-Pacific sites over the last 25 years. As of May 2022,  Novotech has over 
2,500 FTEs working across our offices in 12 geographies in Asia-Pacific and the 
United States.


For more information, please contact:
Paul Oestreicher
External Communications Director
Tel : +1-917-522-4692
Paul.Oestreicher@3ds.com 

Source: Medidata